TBIO -- Is Its Stock Price A Worthy Investment? Learn More. (2024)


  • TBIO Home
  • News
  • Ratings
  • Charts
  • Price Target

$0.33 0.05 (-12.89%)
Quote Time: Apr 18 3:57pm

Translate Bio, Inc. (TBIO): $0.33

0.05 (-12.89%)

Add TBIO to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#144 of 375

in industry

See All 'A' Rated Buy Stocks

TBIO Price/Volume Stats

Current price $0.33 52-week high $3.01
Prev. close $0.38 52-week low $0.30
Day low $0.31 Volume 266,500
Day high $0.46 Avg. volume 650,269
50-day MA $0.45 Dividend yield N/A
200-day MA $0.77 Market Cap 9.96M

TBIO Stock Price Chart Interactive Chart >

Translate Bio, Inc. (TBIO) Company Bio

Translate Bio, Inc., a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency. It has strategic alliances with Sanofi Pasteur. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is based in Lexington, Massachusetts.

Most Popular Stories View All

• How Low Could Stocks Go?

• 3 Biotech Stocks to Buy to Power Through April

• Check out These 3 Internet Stocks for Potential Gains

• Top 3 Financial Services Stocks With Unstoppable Momentum

• Updated 2024 Stock Market Outlook

View All Top stories

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

TBIO Latest News Stream

Event/Time News Detail
Loading, please wait...

View All TBIO News

TBIO Latest Social Stream

Loading social stream, please wait...

View Full TBIO Social Stream

Latest TBIO News From Around the Web

Below are the latest news stories about TELESIS BIO INC that investors may wish to consider to help them evaluate TBIO as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers onMonday

It's time to start the week with a breakdown of the biggest pre-market stock movers that are worth watching on Monday morning!

William White on InvestorPlace | November 27, 2023

Telesis Bio Reports Third Quarter 2023 Financial Results

SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the third quarter of 2023. “This quarter, we continued to drive adoption of our instruments and kits, make progress against important collaborations, advance our mRNA strategy, and strengthen both our Board of Directors and Management Team,” said Todd R. Nelson, PhD, CEO, and founder of Telesis Bio. Highlights Strengt

Yahoo | November 13, 2023

Telesis Bio to Report Third Quarter Financial Results on Monday, November 13, 2023

SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2023 financial results on Monday, November 13, 2023, after the market closes. The press release can be accessed via the Investor section of Telesis Bio’s website at https://ir.telesisbio.com/. About Telesis BioTelesis Bio is empowering scientists with the ability to create novel, synthetic biology-enabled

Yahoo | November 7, 2023

Telesis Bio Announces Commercial Release of Cell-free Amplification Kit for Generation of Transfection-scale DNA

New Kit offers BioXp automation workflow from candidate sequence to amplified DNA in daysSAN DIEGO, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced the commercial release of its BioXp® De novo Cloning and Amplification kit on the BioXp 3250 and BioXp 9600 systems. This cell-free DNA amplification kit provides an efficient automated solution for building and amplifying DNA constructs to transfecti

Yahoo | November 3, 2023

Telesis Bio Announces Commercial Release of BioXp® NGS Library Prep Kit for WGS

New Kit expands suite of NGS Library Prep solutions on the BioXp® System Enabling Speed and Efficiency for Whole genome sequencing (WGS) applications with the Automated Molecular Biology WorkstationSAN DIEGO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced the commercial release of its BioXp® NGS Library Prep kit for Whole Genome Sequencing on the BioXp 3250 and BioXp 9600 systems. This NGS libr

Yahoo | September 28, 2023

Read More 'TBIO' Stories Here

TBIO Price Returns

1-mo -27.15%
3-mo 4.00%
6-mo -63.19%
1-year -88.30%
3-year N/A
5-year N/A
YTD -17.29%
2023 -66.75%
2022 -88.89%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

'); //tr.push('' + json.results[i].symbol + ''); //tr.push('' + json.results[i].company + ''); tr.push('' + headline); if (json.results[i].is_premium == 1) { tr.push(' Premium'); } tr.push(''); //tr.push('' + json.results[i].price_when_added + ''); // tr.push('' + json.results[i].day_close + ''); //tr.push('' + json.results[i].day_change + '
' + json.results[i].day_pct_change + ''); //tr.push('' + json.results[i].ttm_pct_change_formatted + ''); //tr.push('' + json.results[i].grade + ""); tr.push(''); } } $(tr.join('')).appendTo($('table#news-stream tbody')).slideDown("slow"); }); } home_get_snippets("all"); function ticker_get_social(symbol) { $.getJSON('//stocknews.com/wp-content/themes/strappress-child/includes/social-json.php?symbol=TBIO', function (soc) { $("#social-stream").html(""); var social=[]; for (var i = 0; i < soc.length; i++) { social.push('

'); social.push(''+ soc[i].real_name +' '); social.push(''+ soc[i].time_since +' on '+ soc[i].service +''); social.push('

'+ soc[i].message +'

'); social.push('

'); /*

TBIO -- Is Its Stock Price A Worthy Investment? Learn More. (5) on

*/ } $(social.join('')).appendTo($('#social-stream')); }); } ticker_get_social('TBIO'); function ticker_get_dividends(symbol) { $.getJSON('//stocknews.com/wp-content/themes/strappress-child/includes/dividend-json.php?symbol=TBIO&max_records=10', function (json) { $("#dividend-stream tbody").html(""); var dividend=[]; for (var i = 0; i < json.results.length; i++) { dividend.push(''); dividend.push('' + json.results[i].eventDate + ''); dividend.push('' + json.results[i].eventType + ''); dividend.push('' + json.results[i].value_formatted + ''); dividend.push('' + json.results[i].pct_change_formatted + ''); dividend.push(''); } $(dividend.join('')).prependTo($('#dividend-stream')).slideDown("slow"); }); } ticker_get_dividends('TBIO'); $('#snippet-type').on('change', function(){ var selected = $(this).find("option:selected").val(); home_get_snippets(selected); }); $('#watchlist-add').change(function() { this.form.submit(); });
TBIO -- Is Its Stock Price A Worthy Investment? Learn More. (2024)
Top Articles
Latest Posts
Article information

Author: Prof. Nancy Dach

Last Updated:

Views: 5503

Rating: 4.7 / 5 (57 voted)

Reviews: 88% of readers found this page helpful

Author information

Name: Prof. Nancy Dach

Birthday: 1993-08-23

Address: 569 Waelchi Ports, South Blainebury, LA 11589

Phone: +9958996486049

Job: Sales Manager

Hobby: Web surfing, Scuba diving, Mountaineering, Writing, Sailing, Dance, Blacksmithing

Introduction: My name is Prof. Nancy Dach, I am a lively, joyous, courageous, lovely, tender, charming, open person who loves writing and wants to share my knowledge and understanding with you.